Technical Analysis for KYKOF - Kyowa Hakko Kogyo

Grade Last Price % Change Price Change
grade C 17.0 5.59% 0.9000
KYKOF closed up 5.59 percent on Monday, August 12, 2019, on 5 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical KYKOF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup 5.59%
Stochastic Buy Signal Bullish 5.59%
Gapped Up Strength 5.59%
Oversold Stochastic Weakness 5.59%
Narrow Range Bar Range Contraction 8.49%
Below Lower BB Weakness 8.49%
Gapped Down Weakness 8.49%

Older signals for KYKOF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Kyowa Hakko Kirin Co., Ltd., a research and development-based life sciences company, manufactures and markets pharmaceuticals and bio-chemicals worldwide. Its products include ABSTRAL, a novel sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; and REGPARA, a new class of agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment for nausea and vomiting. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Medicine Biotechnology Cancer Pharmaceuticals Biology Chemotherapy Hypertension Allergies Constipation Nausea Vomiting Acute Lymphoblastic Leukemia Angina Pectoris Cytokines Erythropoiesis Stimulating Agent Growth Factors Amgen Erythropoietin Kirin Secondary Hyperparathyroidism Bio Chemicals Kirin Holdings Kyowa Hakko Kirin
Is KYKOF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 22.5
52 Week Low 13.25
Average Volume 4,047
200-Day Moving Average 17.1367
50-Day Moving Average 18.6232
20-Day Moving Average 17.498
10-Day Moving Average 16.778
Average True Range 0.5884
ADX 9.21
+DI 44.5395
-DI 47.0804
Chandelier Exit (Long, 3 ATRs ) 17.7248
Chandelier Exit (Short, 3 ATRs ) 17.4352
Upper Bollinger Band 19.2275
Lower Bollinger Band 15.7685
Percent B (%b) 0.36
BandWidth 19.767973
MACD Line -0.6155
MACD Signal Line -0.5386
MACD Histogram -0.0769
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.0000
Resistance 3 (R3) 17.0000 17.0000 17.0000
Resistance 2 (R2) 17.0000 17.0000 17.0000 17.0000
Resistance 1 (R1) 17.0000 17.0000 17.0000 17.0000 17.0000
Pivot Point 17.0000 17.0000 17.0000 17.0000 17.0000
Support 1 (S1) 17.0000 17.0000 17.0000 17.0000 17.0000
Support 2 (S2) 17.0000 17.0000 17.0000 17.0000
Support 3 (S3) 17.0000 17.0000 17.0000
Support 4 (S4) 17.0000